Johnson & Johnson downgraded by Daiwa Securities with a new price target
$JNJ
Biotechnology: Pharmaceutical Preparations
Health Care
Daiwa Securities downgraded Johnson & Johnson from Outperform to Neutral and set a new price target of $150.00 from $160.00 previously